The role of Th17 and regulatory T cells (TREGs) in immunomodulation of experimental periapical lesions / Papel das células Th17 e T reguladoras (TREGs) na imunomodulação de lesões periapicais experimentais

A patogênese das lesões periapicais é determinada pelo equilíbrio entre a resposta imune pró-inflamatória do hospedeiro e a resposta anti-inflamatória/reparo. Diferentes subtipos de linfócitos e seus produtos têm sido implicados na patogênese dessas lesões, tais como as células T reguladoras (Tregs) e Th17. Enquanto as Tregs parecem ser potenciais agentes imuno-reguladores, Th17 parece estar associada à maior severidade da doença. Neste estudo, foram investigados o envolvimento de Tregs e Th17, além do impacto de diferentes terapias na progressão de lesões periapicais experimentais. Para isso, lesões periapicais foram induzidas (exposição pulpar e inoculação bacteriana) em camundongos C57BL/6, IL- 17KO e CCR4KO tratados com anticorpos anti-GITR (inibe a função de Treg) ou com CCL22p, partículas de ácido poliláctico-glicólico (induz a migração de Tregs). Além disso, os camundongos WT foram tratados com anti-RANKL utilizando protocolos contínuos ou intermitentes, ou com anti-TNF como controle. Posteriormente, analisou-se o fluxo e fenótipo de Tregs e Th17, perda óssea periapical e expressão de citocinas inflamatórias/imunológicas e marcadores de reparo (RealTimePCRarray, ELISA). A inibição de Tregs (depleção de CCR4 ou terapia anti-GITR), aumentou significantemente a severidade da lesão, associada com o aumento da expressão de citocinas pró-inflamatórias, Th1, Th17 e mediadores de destruição tecidual em paralelo com a diminuição dos marcadores de Treg e de reparo. A liberação local de CCL22 no canal radicular resultou na migração de Treg, dependente de CCR4, levando à modulação da lesão periapical, associada com a diminuição da expressão de marcadores pró-inflamatórios e de destruição tecidual em paralelo com o aumento dos marcadores de Tregs e de reparo. O tratamento anti-RANKL impediu o desenvolvimento da lesão, mas provocou uma resposta inflamatória contínua caracterizada pela elevada expressão de citocinas pró-inflamatórias e mediadores de destruição tecidual e diminuição da expressão dos marcadores de Tregs e de reparo. Este tratamento levou à recidiva da lesão e foi associado com o aumento da razão células TCD4 efetoras/supressoras e com o perfil de expressão gênica de lesões ativas. O tratamento anti-TNF limitou a progressão das lesões e não promoveu sua recidiva após o término da terapia, estando associado à resposta do hospedeiro atenuada. Por fim, a ausência de IL-17 resultou em lesões menos severas, associadas com o aumento da expressão de marcadores de reparo e citocinas anti-inflamatórias, em paralelo com a menor expressão de marcadores de destruição tecidual e citocinas pró-inflamatórias. De fato, observou-se menor concentração de osteoclastos, neutrófilos e células inflamatórias, na ausência de IL-17. Conclui-se, portanto, que as células T reguladoras são essenciais no controle da lesão periapical, enquanto as células Th17 acentuam a severidade dessas lesões. Comparando com outras estratégias clínicas, tais como a terapia anti-RANKL que perpetua a resposta inflamatória do hospedeiro levando a recidiva da lesão, a quimioatração de Treg bem como a inibição de Th17 podem ser estratégias promissoras para o manejo clínico das lesões periapicais.(AU)

The pathogenesis of periapical lesions is determined by the balance between host proinflammatory immune response and counteracting anti-inflammatory and reparative responses. In this context, different subtypes of lymphocytes and their products have been implicated in periapical lesion pathogenesis, such as regulatory T cells (Tregs) and Th17. While Tregs has been demonstrated as potential immunoregulatory agents, Th17 has been correlated with greater severity of disease. In this study, we investigated (in a cause-and-effect manner) the involvement of Tregs and Th17, besides the impact of different therapies in the progression of experimental periapical lesions. With this aim, periapical lesions were induced (pulp exposure and bacterial inoculation) in C57Bl/6 (wild-type), IL-17KO and CCR4KO mice and treated with anti­glucocorticoid-induced TNF receptor family regulated gene (anti-GITR) to inhibit Treg function or alternatively with CCL22-releasing, poly lactic-glycolic acid particles to induce site-specific migration of Tregs. Furthermore, WT mice were treated with anti-RANKL using continuous or intermittent protocols, and with anti-TNF therapy as a control. After treatment, lesions were analyzed for Treg or Th17 influx and phenotype, overall periapical bone loss, and inflammatory/immunologic and wound healing marker expression (RealTimePCRarray, ELISA). Treg inhibition by anti-GITR or CCR4 depletion results in a significant increase in periapical lesion severity, associated with upregulation of proinflammatory, Th1, Th17, and tissue destruction markers in parallel with decreased Treg and healing marker expression. The local release of CCL22 in the root canal system resulted in the promotion of Treg migration in a CCR4-dependent manner, leading to the arrest of periapical lesion progression, associated with down regulation of proinflammatory and tissue destruction markers in parallel with increased Treg and healing marker expression. Anti-RANKL treatment arrested lesion development, but prompted a continuous inflammatory response characterized by unremitting elevated expression of proinflammatory cytokines and tissue destructive mediators, and decreased expression of Tregs and wound healing markers levels. This treatment triggered lesion development relapse and was associated with high TCD4 effector/suppressor cells ratio and active lesions gene expression signature. Anti-TNF treatment limits lesions progression and does not drives lesions relapse upon cessation, being associated with attenuated host response. Finally, the absence of IL-17 results in a significant decrease in periapical lesions severity, associated with upregulation of healing markers and antiinflammatory cytokines, in parallel with decreased expression of tissue destruction markers and proinflammatory cytokines. Indeed, histomorphometric analysis showed lower concentration of osteoclasts, neutrophils and mononuclear cells in periapical lesions without IL-17. Therefore, we concluded that regulatory T cells are essential in the control of apical periodontitis, while Th17 cells accentuate the lesions severity. Compared with other clinical strategies, such as anti-RANKL therapy, which perpetuates the host inflammatory response prompting lesion relapse, chemoattraction of Treg as well as inhibition of Th17 may be promising strategies for the clinical management of periapical lesions.(AU)

Using agents that suppress bone remodeling to treat or prevent joint disease: quo vadis?

Treatment of osteoarthritis (OA) with antiremodeling agents has had a mixed record of results. It is likely that remodeling suppression is only effective when used in the early phases of OA, before significant progression. Animal and human studies largely bear this out. Treatment of young mice with a RANKL inhibitor suppresses bone resorption and prevents OA progression. Likewise, bisphosphonate treatments in rodents and rabbits with induced injury or inflammatory arthritis, reduced cartilage degeneration when administered preemptively, but later administration did not. The increased prevalence of OA in women after the menopause, and presence of estrogen receptors in joint tissues, suggests that treatment with estrogens or Selective Estrogen Receptor Modulators may be effective. However, in clinical trials of knee and hip, results show decreased or increased risk for OA, or no effect. Raloxifene had positive effects in animal models, but no effect in human studies. More recent potential treatments such as strontium ranelate or cathepsin-K inhibitors may be effective, but may work directly on the cartilage rather than through their well-known effects on bone. The conclusion from these studies is that anti-remodeling agents must be administered pre-emptively or in the very early stages of disease to be effective. This means that better imaging techniques or identification of early structural changes in bone that occur before progressive cartilage destruction must be developed. (AU)